Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Norbert Vey

Showing results (171-180 of 251) with videos related to

Pageof 26
Sort By:
Haematologica|October 14, 2011
Treatment with lenalidomide does not appear to increase the risk of progression in lower risk myelodysplastic syndromes with 5q deletion. A comparative analysis by the Groupe Francophone des MyelodysplasiesLionel Adès, Fabien Le Bras, Marie Sebert, et al.
Haematologica|October 3, 2009
TET2 gene mutation is a frequent and adverse event in chronic myelomonocytic leukemiaOlivier Kosmider, Véronique Gelsi-Boyer, Marion Ciudad, et al.
Leukemia Research|July 1, 2011
Treatment by Lenalidomide in lower risk myelodysplastic syndrome with 5q deletion--the GFM experienceFabien Le Bras, Marie Sebert, Charikleia Kelaidi, et al.
Cancers|January 8, 2020
Clofarabine Improves Relapse-Free Survival of Acute Myeloid Leukemia in Younger Adults with Micro-Complex KaryotypeLaurène Fenwarth, Nicolas Duployez, Xavier Thomas, et al.
American Journal of Hematology|August 23, 2012
Role of autologous hematopoietic stem cell transplantation according to the NPM1/FLT3-ITD molecular status for cytogenetically normal AML patients: a GOELAMS studyRomain Guièze, Pascale Cornillet-Lefebvre, Bruno Lioure, et al.
Blood|March 22, 2003
Prognosis of inv(16)/t(16;16) acute myeloid leukemia (AML): a survey of 110 cases from the French AML IntergroupJacques Delaunay, Norbert Vey, Thierry Leblanc, et al.
European Journal of Haematology|January 17, 2013
Allogeneic stem cell transplantation for chronic myelomonocytic leukemia: a report from the Societe Francaise de Greffe de Moelle et de Therapie CellulaireSophie Park, Myriam Labopin, Ibrahim Yakoub-Agha, et al.
Cancer Research|October 4, 2017
JAM-C Identifies Src Family Kinase-Activated Leukemia-Initiating Cells and Predicts Poor Prognosis in Acute Myeloid LeukemiaMaria De Grandis, Florence Bardin, Cyril Fauriat, et al.
Oncotarget|September 20, 2019
Correction: NKp30 expression is a prognostic immune biomarker for stratification of patients with intermediate-risk acute myeloid leukemiaAnne-Sophie Chretien, Cyril Fauriat, Florence Orlanducci, et al.
Oncotarget|May 27, 2017
NKp30 expression is a prognostic immune biomarker for stratification of patients with intermediate-risk acute myeloid leukemiaAnne-Sophie Chretien, Cyril Fauriat, Florence Orlanducci, et al.
Pageof 26

Showing results (171-180 of 251) with videos related to

Sort By:
Pageof 26
Haematologica|October 14, 2011
Treatment with lenalidomide does not appear to increase the risk of progression in lower risk myelodysplastic syndromes with 5q deletion. A comparative analysis by the Groupe Francophone des MyelodysplasiesLionel Adès, Fabien Le Bras, Marie Sebert, et al.
Haematologica|October 3, 2009
TET2 gene mutation is a frequent and adverse event in chronic myelomonocytic leukemiaOlivier Kosmider, Véronique Gelsi-Boyer, Marion Ciudad, et al.
Leukemia Research|July 1, 2011
Treatment by Lenalidomide in lower risk myelodysplastic syndrome with 5q deletion--the GFM experienceFabien Le Bras, Marie Sebert, Charikleia Kelaidi, et al.
Cancers|January 8, 2020
Clofarabine Improves Relapse-Free Survival of Acute Myeloid Leukemia in Younger Adults with Micro-Complex KaryotypeLaurène Fenwarth, Nicolas Duployez, Xavier Thomas, et al.
American Journal of Hematology|August 23, 2012
Role of autologous hematopoietic stem cell transplantation according to the NPM1/FLT3-ITD molecular status for cytogenetically normal AML patients: a GOELAMS studyRomain Guièze, Pascale Cornillet-Lefebvre, Bruno Lioure, et al.
Blood|March 22, 2003
Prognosis of inv(16)/t(16;16) acute myeloid leukemia (AML): a survey of 110 cases from the French AML IntergroupJacques Delaunay, Norbert Vey, Thierry Leblanc, et al.
European Journal of Haematology|January 17, 2013
Allogeneic stem cell transplantation for chronic myelomonocytic leukemia: a report from the Societe Francaise de Greffe de Moelle et de Therapie CellulaireSophie Park, Myriam Labopin, Ibrahim Yakoub-Agha, et al.
Cancer Research|October 4, 2017
JAM-C Identifies Src Family Kinase-Activated Leukemia-Initiating Cells and Predicts Poor Prognosis in Acute Myeloid LeukemiaMaria De Grandis, Florence Bardin, Cyril Fauriat, et al.
Oncotarget|September 20, 2019
Correction: NKp30 expression is a prognostic immune biomarker for stratification of patients with intermediate-risk acute myeloid leukemiaAnne-Sophie Chretien, Cyril Fauriat, Florence Orlanducci, et al.
Oncotarget|May 27, 2017
NKp30 expression is a prognostic immune biomarker for stratification of patients with intermediate-risk acute myeloid leukemiaAnne-Sophie Chretien, Cyril Fauriat, Florence Orlanducci, et al.
Pageof 26